Cargando…

Trastuzumab Cardiotoxicity in Patients with Breast Cancer

Detalles Bibliográficos
Autores principales:	Freitas, Aguinaldo Figueiredo, Rassi, Salvador
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Cardiologia 2014
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987332/ https://www.ncbi.nlm.nih.gov/pubmed/24676377 http://dx.doi.org/10.5935/abc.20140008

Ejemplares similares

Subclinical Ventricular Dysfunction Detected by Speckle-Tracking Two Years after Use of Anthracycline
por: Freitas Jr., Aguinaldo Figueiredo, et al.
Publicado: (2015)

Echocardiographic strategy for early detection of cardiotoxicity of doxorubicin: a prospective observational study
por: Sampaio, Diogo Pereira Santos, et al.
Publicado: (2022)

Detection of Subclinical Trastuzumab-Induced Cardiotoxicity in Patients with Breast Cancer
por: dos Santos, Marília Harumi Higuchi
Publicado: (2013)

Risks of trastuzumab‐related cardiotoxicity in breast cancer patients in Taiwan
por: Chang, Wei‐Ting, et al.
Publicado: (2021)

Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer
por: Marinko, Tanja, et al.
Publicado: (2014)

Coq10 for preventing cardiotoxicity in breast cancer patients treated with trastuzumab
por: Al-Hammadi, Nawal, et al.
Publicado: (2023)

Antioxidant Protection against Trastuzumab Cardiotoxicity in Breast Cancer Therapy
por: Méndez-Valdés, Gabriel, et al.
Publicado: (2023)

Trastuzumab-associated autoimmune thyroid disease in a patient with metastatic breast cancer
por: Min, Hong Ki, et al.
Publicado: (2016)

Acute Cardiotoxicity With Concurrent Trastuzumab and Hypofractionated Radiation Therapy in Breast Cancer Patients
por: Sayan, Mutlay, et al.
Publicado: (2019)

A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients
por: Matos, Erika, et al.
Publicado: (2016)

Early Cardiotoxicity after Adjuvant Concomitant Treatment with Radiotherapy and Trastuzumab in Patients with Breast Cancer
por: Marinko, Tanja, et al.
Publicado: (2018)

Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: A meta-analysis
por: Jawa, Zeeshan, et al.
Publicado: (2016)

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017)

Loperamide abuse and cardiotoxicity
por: Smith, Nichole A., et al.
Publicado: (2017)

Risk of Trastuzumab-Related Cardiotoxicity in Early Breast Cancer Patients: A Prospective Observational Study
por: Xue, Jian, et al.
Publicado: (2014)

Valvular heart disease as a possible predictor of trastuzumab-induced cardiotoxicity in patients with breast cancer
por: Sato, Akihiko, et al.
Publicado: (2019)

Cardioncological Approach for Trastuzumab Therapy in Breast Cancer Patients With Cardiotoxicity: Impact on Adherence and Clinical Outcome
por: Fabiani, Iacopo, et al.
Publicado: (2020)

NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients
por: Blancas, Isabel, et al.
Publicado: (2020)

The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer Treatment
por: Lin, Mengmeng, et al.
Publicado: (2022)

Mild Cardiotoxicity and Continued Trastuzumab Treatment in the Context of HER2-Positive Breast Cancer
por: de la Brassinne Bonardeaux, Orianne, et al.
Publicado: (2023)

BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model
por: Dirican, Ebubekir
Publicado: (2020)

A commentary on operamide and cardiotoxicity
por: Rajayer, Salil R., et al.
Publicado: (2017)

High-sensitivity troponin T as a marker to predict cardiotoxicity in breast cancer patients with adjuvant trastuzumab therapy
por: Katsurada, Kenichi, et al.
Publicado: (2014)

Trastuzumab resumption after extremely severe cardiotoxicity in metastatic breast cancer patient: a case report
por: Minichillo, Santino, et al.
Publicado: (2017)

Biomarker panel for early screening of trastuzumab -induced cardiotoxicity among breast cancer patients in west virginia
por: Pillai, Sneha S., et al.
Publicado: (2022)

Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis
por: Soares, L.R., et al.
Publicado: (2023)

Three-Year Outcomes Following Permissive Cardiotoxicity in Patients on Trastuzumab
por: Zhou, Shijie, et al.
Publicado: (2023)

Trastuzumab-induced cardiotoxicity in early breast cancer over a 10-year period in Uruguay
por: Castillo, Cecilia, et al.
Publicado: (2022)

Shorter course of trastuzumab: Caveat emptor
por: Venniyoor, Ajit
Publicado: (2011)

Adjuvant Trastuzumab Is Required in Human Epidermal Growth Factor Receptor 2-Positive Node-Negative Breast Cancer Patients Regardless of Tumour Size
por: Bender, Laura, et al.
Publicado: (2020)

The influence of steroid receptor status on the cardiotoxicity risk in HER2-positive breast cancer patients receiving trastuzumab
por: Huszno, Joanna, et al.
Publicado: (2015)

The cardioprotective role of trimetazidine on cisplatin-induced cardiotoxicity
por: Küçük, Murathan, et al.
Publicado: (2020)

Can ARNI Prevent Doxorubicin-Induced Cardiotoxicity?
por: Özgür Barış, Veysel, et al.
Publicado: (2022)

Severe hypoglycemia with trastuzumab: An unseen adverse event
por: Amrith, B. P., et al.
Publicado: (2019)

A Case of Trastuzumab-Associated Cardiomyopathy Presenting as an Acute Coronary Syndrome: Acute Trastuzumab Cardiotoxicity
por: Hidalgo, Sylvana, et al.
Publicado: (2013)

A novel HSP90 inhibitor targeting the C-terminal domain attenuates trastuzumab resistance in HER2-positive breast cancer
por: Park, Jung Min, et al.
Publicado: (2020)

Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer
por: Allegretti, Matteo, et al.
Publicado: (2021)

Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials
por: Rygiel, Katarzyna
Publicado: (2016)

Global Longitudinal Strain Accuracy for Cardiotoxicity Prediction in a Cohort of Breast Cancer Patients During Anthracycline and/or Trastuzumab Treatment
por: Gripp, Eliza de Almeida, et al.
Publicado: (2018)

Long-term irreversible trastuzumab-induced cardiotoxicity for metastatic breast cancer in a patient without cardiac risk factors
por: Tanaka, Satoru, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_0a5ctj6123bqh410j5o7it7b5e